Ideaya Biosciences Inc's Customers Performance

Name: Ideaya Biosciences Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

IDYA

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


IDYA's Source of Revenues		During the corresponding time, Ideaya Biosciences Inc sequentially revenue grew by 35.02 %. While revenue at the Ideaya Biosciences Inc 's corporate clients • List of IDYA Customers

for the same period Ideaya Biosciences Inc sequentially revenue grew by 35.02 %.

• List of IDYA Customers

Ideaya Biosciences Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Ideaya Biosciences Inc's Comment on Sales, Marketing and Customers

News about Ideaya Biosciences Inc Contracts

In an exciting development for the pharmaceutical industry, IDEAYA Biosciences, Inc. (Nasdaq IDYA) has anno...

Breaking Barriers: IDEAYA Biosciences Unveils Promising BsADC Candidate in Challenging Market Landscape In an exciting development for the pharmaceutical industry, IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has announced progress on its latest drug conjugate candidate, IDEAYAB7H3/PTK7 ADC (IDE034). This novel compound represents a groundbreaking advancement in the field of antibody-drug conjugates (ADCs), specifically designed to target the B7H3/PTK7 pathways. As the company capitalizes on its proprietary RenLite platform, the prospects for IDE034 are indeed promising.ADC technology has been a beacon of hope in tailored cancer therapies, marrying the precision of monoclonal antibodies with the potency of cytoto...

Biocytogen and IDEAYA Biosciences Forge Partnership to Develop Pioneering B7H3/PTK7 Bispecific Antibody-Drug Conjug...

In a significant move that promises to advance the field of targeted cancer therapies, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., recently announced an option and license agreement with IDEAYA Biosciences, Inc. This agreement centers around a groundbreaking bispecific antibody-drug conjugate (BsADC) program targeting B7H3 and PTK7, a combination that could set the stage for a potential first-in-class therapeutics. Background on Biocytogen and IDEAYA BiosciencesBiocytogen, a global biopharmaceutical company listed on the Hong Kong Stock Exchange under the ticker 02315, has gained recognition for its innovations in antibody discovery. Its focus on antibody-drug conjugates (ADCs) aligns with current trend...

IDYA's Stock Performance relative to it's Customers

IDYA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Ideaya Biosciences Inc	3,536.08	49.87	-140.06	145
SUBTOTAL	0.00	0.00	0.00	-

Sources: Ideaya Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ideaya Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Ideaya Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.